All stock lists
Bicycle Therapeutics PLC (NASDAQ:BCYC)
GB · Delayed Price · Currency is USD
Healthcare · Biotechnology
3.55-0.09 (-2.47%)
Insider Score
––Not scored
BCYC Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
BCYC analyst forecast
BCYC analyst consensus
Moderate Buy1 ratings
Buy 1 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
BCYC 12-month price target
No published price targets in the last 12 months.
Best analysts covering BCYC
- Oppenheimer33%success rate · 3 calls
- Needham20%success rate · 20 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
BCYC analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | Needham | Buy | — | — | Reiterated | 2026-07-30 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2026-04-08 |
| — | Needham | Buy | — | — | Reiterated | 2026-03-18 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2026-03-18 |
| — | RBC Capital | Sector Perform | — | — | Reiterated | 2026-03-18 |
| — | Citizens | Market Outperform | — | — | Reiterated | 2026-03-18 |
| — | Citizens | Market Outperform | — | — | Reiterated | 2025-10-31 |
| — | RBC Capital | Sector Perform | — | — | Downgraded | 2025-10-31 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2025-08-12 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2025-08-12 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2025-08-11 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-07-17 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2025-05-06 |
| — | Needham | Buy | — | — | Reiterated | 2025-05-02 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-05-02 |
| — | B. Riley Securities | Neutral | — | — | Reiterated | 2025-05-02 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2025-05-02 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-05-01 |
| — | Needham | Buy | — | — | Reiterated | 2025-04-29 |
| — | Needham | Buy | — | — | Reiterated | 2025-04-09 |
| — | Needham | Buy | — | — | Reiterated | 2025-03-11 |
| — | Citizens Capital Markets | Market Outperform | — | — | Reiterated | 2025-02-26 |
| — | Needham | Buy | — | — | Reiterated | 2025-02-26 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-02-26 |
| — | Stephens & Co. | Equal Weight | — | — | Reiterated | 2025-01-22 |
| — | Needham | Buy | — | — | Reiterated | 2025-01-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-01-13 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2024-12-18 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-12-16 |
| — | B. Riley Securities | Neutral | — | — | Reiterated | 2024-12-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-11-01 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2024-11-01 |
| — | Needham | Buy | — | — | Reiterated | 2024-10-31 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-10-24 |
| — | Needham | Buy | — | — | Reiterated | 2024-10-24 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-09-16 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2024-09-16 |
| — | Needham | Buy | — | — | Reiterated | 2024-09-16 |
| — | Needham | Buy | — | — | Reiterated | 2024-09-09 |
| — | B. Riley Securities | Neutral | — | — | Downgraded | 2024-08-07 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-08-07 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2024-08-07 |
| — | Needham | Buy | — | — | Reiterated | 2024-08-07 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-05-03 |
| — | Needham | Buy | — | — | Reiterated | 2024-04-10 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-02-21 |
| — | Needham | Buy | — | — | Reiterated | 2024-02-21 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2024-02-21 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2023-12-20 |
| — | Needham | Buy | — | — | Reiterated | 2023-12-15 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2023-11-08 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2023-11-03 |
| — | B. Riley Securities | Buy | — | — | Upgraded | 2023-09-12 |
| — | Needham | Buy | — | — | Reiterated | 2023-09-12 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2023-09-12 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2023-09-12 |
| — | B. Riley Securities | Buy | — | — | Upgraded | 2023-09-11 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2023-09-07 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2023-08-04 |
| — | Needham | Buy | — | — | Reiterated | 2023-08-04 |
BCYC earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-03-17 | -0.94 | -0.29 | $7.0M | $48.0M |
| 2026-04-30 | -0.52 | -0.87 | $7.5M | $887K |
| 2026-07-30 | -0.56 | -0.72 | $4.2M | $629K |
| 2026-10-29 | -0.40 | 0.00 | $12.2M | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.